Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:16:29 EST Sat 13 Dec 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:ERNA - ERNEXA THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ERNA - Q0.11.33·1.700.11.36-0.12-8.132.0332901.47  1.47  1.342314.40  1.0917:59:21Dec 0815 min RT 2¢

Recent Trades - Last 10 of 290
Time ETExPriceChangeVolume
17:59:21Q1.34-0.1430
16:10:03Q1.36-0.121
16:04:09Q1.36-0.121
16:00:02Q1.36-0.121
16:00:02Q1.36-0.1246
16:00:02Q1.36-0.1250
16:00:02Q1.36-0.1250
16:00:02Q1.36-0.1249
16:00:02Q1.36-0.1250
16:00:02Q1.36-0.1255

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-12-08 08:30U:ERNANews ReleaseErnexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer
2025-12-03 08:30U:ERNANews ReleaseErnexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting
2025-12-02 08:50U:ERNANews ReleaseErnexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG
2025-11-11 07:00U:ERNANews ReleaseErnexa Therapeutics to Present at Oxford Global's Cell 2025
2025-11-10 08:35U:ERNANews ReleaseErnexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials
2025-11-06 09:15U:ERNANews ReleaseErnexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor "What This Means" Platform
2025-10-29 10:32U:ERNANews Release/C O R R E C T I O N -- Cellipont Bioservices/
2025-10-29 08:33U:ERNANews ReleaseCellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer
2025-10-01 08:30U:ERNANews ReleaseErnexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa
2025-09-29 08:30U:ERNANews ReleaseErnexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit
2025-09-17 08:30U:ERNANews ReleaseErnexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research
2025-09-10 08:30U:ERNANews ReleaseErnexa Therapeutics Provides Update on Operational Excellence and Performance
2025-09-03 09:30U:ERNANews ReleaseErnexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference
2025-07-09 08:30U:ERNANews ReleaseErnexa Therapeutics Regains Compliance with Nasdaq Listing Requirements
2025-06-25 08:30U:ERNANews ReleaseErnexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development
2025-06-24 08:30U:ERNANews ReleaseErnexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement
2025-06-10 09:30U:ERNANews ReleaseErnexa Therapeutics Announces 1-for-15 Reverse Stock Split
2025-05-28 08:30U:ERNANews ReleaseErnexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025
2025-05-14 08:30U:ERNANews ReleaseErnexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations
2025-05-08 08:32U:ERNANews ReleaseErnexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference